STOCK TITAN
  1. Home
  2. News
  3. ATHX

Athersys Inc - ATHX STOCK NEWS

Welcome to our dedicated news page for Athersys (Ticker: ATHX), a resource for investors and traders seeking the latest updates and insights on Athersys.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Athersys's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Athersys's position in the market.

News
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
Rhea-AI Summary
Athersys, Inc. (OTC: ATHX) Announces Financial Results and Business Update, Including Interim Analysis of Phase 3 MASTERS-2 Clinical Trial for MultiStem Cell Therapy. The company also secured funding through warrant exercise and a Memorandum of Understanding with Healios for global rights to develop and commercialize MultiStem for the treatment of Acute Respiratory Distress Syndrome (ARDS). Athersys appointed Ms. Jane Wasman as Chair of the Board of Directors. Financially, the third quarter of 2023 showed a decrease in revenue, research and development expenses, and general and administrative expenses compared to the same period in 2022, resulting in a net loss of $(3.8) million. Cash and cash equivalents were $1.0 million as of September 30, 2023, compared with $9.0 million as of December 31, 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.79%
Tags
earnings
-
News
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives
Rhea-AI Summary
Athersys announces warrant exercise inducement offer to raise $3.9 million and receives $1.5 million payment from HEALIOS K.K.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios
Rhea-AI Summary
Athersys announces inconclusive results from Phase 3 trial for stroke treatment and enters into MOU with Healios for respiratory distress syndrome treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-60%
Tags
clinical trial
News
Athersys Licenses its Animal Health Assets to Ardent Animal Health
Rhea-AI Summary
Athersys signs licensing agreement with Ardent Animal Health for non-human mammal applications of MAPC technology in the US. Athersys will receive initial fee, milestone payments, and royalties on commercial sales. Ardent also granted rights of first refusal for Athersys' cryogenic storage system. Positive partnership for Athersys in expanding its regenerative medicine applications in animal health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Athersys Director Jane Wasman Appointed Board Chair
Rhea-AI Summary
Athersys, Inc. announces changes to its Board of Directors. Jane Wasman appointed as Board Chair. Her expertise in strategic, operational, and corporate governance matters will be valuable. She is also chair of the board of directors of Sellas Life Sciences and a member of the board of directors of Rigel Pharmaceuticals. Positive for shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
-
News
Grant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney Transplantation
Rhea-AI Summary
Athersys announces grant funding for study on potential use of MultiStem cellular therapy during machine perfusion prior to kidney transplantation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
News
Athersys, Inc. Announces Pricing of $3.5 Million Public Offering
Rhea-AI Summary
Athersys, Inc. announces the pricing of its public offering of common stock and warrants. The offering is expected to raise approximately $3.5 million for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.51%
Tags
offering
-
News
Athersys Reports Second Quarter 2023 Financial Results and Business Highlights
Rhea-AI Summary
Athersys, Inc. (Nasdaq: ATHX) announced financial results for Q2 2023, with $48.8K in revenue compared to $2.3M in Q2 2022. Research and development expenses decreased to $10.6M from $20.8M, and general and administrative expenses decreased to $2.3M from $5.2M. Net loss for Q2 2023 was $(12.9)M, compared to $(23.6)M in Q2 2022. Cash and cash equivalents were $1.8M as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
earnings
-
News
Athersys Appoints Neema Mayhugh, PhD to its Board of Directors
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.38%
Tags
management
News
Athersys to Host Business Update Conference Call on August 9th
Rhea-AI Summary
Athersys, Inc. (NASDAQ: ATHX) will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time. The call will provide an overview of the company's recent clinical and operational progress, including the timing to conduct an interim analysis with MASTERS-2, a Phase 3 pivotal trial of MultiStem treatment in ischemic stroke.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
conferences
Stock ATHX logo
Athersys Inc

OTC:ATHX

ATHX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ATHX Stock Data

833.20k
61.15M
0.77%
4.42%
3.72%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cleveland

About ATHX

athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. we are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. this pipeline includes both stem cell therapy and pharmaceuticals.